Compare D R Horton Inc (DHI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Smith & Nephew plc — how do they compare? D R Horton Inc trades at $146.24 (market cap $42.18B), while Smith & Nephew plc trades at $29.71 (market cap $12.54B). The key difference: D R Horton Inc is far larger — about 3.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| DHI | SNN | |
|---|---|---|
Market Cap | $42.18B | $12.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $38.70 |
52-Week Low | $132.53 | $28.73 |
Enterprise Value | $47.28B | $15.57B |
Dividend Yield | 1.19% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $146.66, down 2.93% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.20 versus $3.02 expected. However, revenue and net income have trended lower from 2023 peaks, with 2025 revenue at $34.25B and net income at $3.59B. The company maintains a reasonable valuation with a P/E of 14.37 and recently declared a $0.45 dividend payable in August 2026.
The outlook is mixed; strong execution and cash returns support the stock, but lowered guidance and margin pressure from elevated mortgage rates pose headwinds. Analyst consensus is nearly evenly split between Buy and Hold, with a $153 price target suggesting modest upside. Key risks include persistent demand softness in housing and competitive disruption from new entrants like Boxabl.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
